Toutes les photos(1)

Key Documents

View All Documentation

1269618

USP

Fenofibrate Related Compound B

Name: Fenofibrate Related Compound B
Brand: USP

United States Pharmacopeia (USP) Reference Standard

Synonyme(s) :

2-[4-(4-Chlorobenzoyl)phenoxy]-2-methylpropionic acid, Fenofibric acid

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme

Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):

C₁₇H₁₅ClO₄

Numéro CAS:

42017-89-0

Poids moléculaire :

318.75

Numéro Beilstein :

2058973

Numéro MDL:

MFCD00792461

Code UNSPSC :

41116107

ID de substance PubChem :

329749839

Nomenclature NACRES :

NA.24

Produits recommandés

Slide 1 of 10

1 of 10

USP

1269607

Fenofibrate Related Compound A

USP

1269629

Fenofibrate Related Compound C

Supelco

PHR2864

Fenofibrate Related Compound A

USP

1184027

Diatrizoic Acid Related Compound A

USP

1269447

Fenofibrate

USP

1356337

Ketorolac Related Compound C

USP

1165656

Deferasirox

USP

1269028

Ezetimibe

F0048005

Fenofibrate impurity A

USP

1584003

Pyrantel pamoate

Qualité

pharmaceutical primary standard

Famille d'API

fenofibrate

Fabricant/nom de marque

USP

Application(s)

pharmaceutical (small molecule)

Format

neat

Chaîne SMILES

O=C(C1=CC=C(OC(C)(C)C(O)=O)C=C1)C2=CC=C(Cl)C=C2

InChI

1S/C17H15ClO4/c1-17(2,16(20)21)22-14-9-5-12(6-10-14)15(19)11-3-7-13(18)8-4-11/h3-10H,1-2H3,(H,20,21)

Clé InChI

MQOBSOSZFYZQOK-UHFFFAOYSA-N

Informations sur le gène

human ... PPARA(5465)

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Catégories apparentées

Étalons de référence analytiques | Sigma-Aldrich

Étalons des instituts de métrologie et des pharmacopées

Chimie analytique

Matériaux de référence

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Fenofibrate Related Compound B USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:

Fenofibrate
Fenofibrate Capsules
Fenofibrate Tablets

Remarque sur l'analyse

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit

Description

Tarif

1269447

Fenofibrate, United States Pharmacopeia (USP) Reference Standard

F0048005

Fenofibrate impurity A, European Pharmacopoeia (EP) Reference Standard

1269607

F0048010

Fenofibrate impurity B, European Pharmacopoeia (EP) Reference Standard

1269629

PHR2864

Pictogrammes

GHS07,GHS09

Mention d'avertissement

Warning

Mentions de danger

H302,H410

Conseils de prudence

P264 - P270 - P273 - P301 + P312 - P391 - P501

Classification des risques

Acute Tox. 4 Oral - Aquatic Acute 1 - Aquatic Chronic 1

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

The Lidose hard capsule formulation of fenofibrate is suprabioavailable compared to the nanoparticle tablet formulation under high-fat fed conditions.

Roger K Verbeeck et al.

Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques, 18(1), 61-67 (2015-04-17)

The therapeutic equivalence of multiple registered fenofibrate formulations, several of which are suprabioavailable and therefore marketed at lower dosage strengths than their reference products, is based on the results of bioequivalence studies. Most of these formulations show a higher bioavailability

Endoplasmic reticulum stress involved in high-fat diet and palmitic acid-induced vascular damages and fenofibrate intervention.

Yunxia Lu et al.

Biochemical and biophysical research communications, 458(1), 1-7 (2015-01-17)

Fenofibrate (FF) is widely used to lower blood lipids in clinical practice, but whether its protective effect on endothelium-dependent vasodilatation (EDV) in thoracic aorta is related with endoplasmic reticulum (ER) stress remains unknown. In this study, female Sprauge Dawley rats

Enzymatic characterization of ELOVL1, a key enzyme in very long-chain fatty acid synthesis.

Martin J A Schackmann et al.

Biochimica et biophysica acta, 1851(2), 231-237 (2014-12-17)

X-linked adrenoleukodystrophy (X-ALD) is a neurometabolic disease that is caused by mutations in the ABCD1 gene. ABCD1 protein deficiency impairs peroxisomal very long-chain fatty acid (VLCFA) degradation resulting in increased cytosolic VLCFA-CoA levels, which are further elongated by the VLCFA-specific

Articles

HPLC Analysis of Fenofibrate and Its Impurities by Following the USP43-NF38 Guidelines Using a Purospher® STAR RP18e Column

An application note concerning the HPLC analysis of fenofibrate and its impurities by following the USP43-NF38 Guidelines using a Purospher® STAR RP18e Column.

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique